

Table 1. Characteristics of the Studies included in the Pooled Analysis of Meat and Prostate Cancer

Study	Country	Follow-up	Baseline cohort size	Age range, years	Total cases	Localized	Advanced (Percent¹)	Advanced (restricted) (Percent¹)	Fatal (Percent)	Low grade	High grade (Percent²)
Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study	Finland	1985-2002	26,987	49-70	1316	828	354(37)	243(19)	270(21)	825	223(21)
Beta-Carotene and Retinol Efficacy Trial	USA	1985-2005	10,474	44-75	736	442	68(11)	45(8)	38(6)	555	79(12)
Campaign Against Cancer and Heart Disease	USA	1989-2009	5,926	18-90	461	250	54(14)	25(6)	46(12)	296	133(31)
Cancer Prevention Study-II Nutrition Cohort	USA	1992-2005	65,923	42-93	6943	5785	458(7)	282(4)	283(4)	5433	1238(19)
Cohort of Swedish Men	Sweden	1998-2008	45,338	45-79	3014	1853	538(18)	398(14)	310(11)	1726	365(17)
European Investigation into Cancer and Nutrition	Europe	1991-2006	142,195	20-97	2727	1337	345(17)	175(9)	248(12)	1325	298(18)
Health Professionals' Follow-Up Study	USA	1986-2008	47,781	32-79	5536	3879	669(13)	321(6)	532(10)	4094	571(12)
The Japan Public Health Center-Based Study Cohort 1	Japan	1990-2004	20,161	40-59	135	78	20(19)	16(15)	5(5)	90	34(27)
The Japan Public Health Center-Based Study Cohort 2	Japan	1993-2004	24,116	40-69	167	84	38(27)	32(23)	12(9)	92	46(33)
Melbourne Collaborative Cohort Study	Australia	1990-2006	14,824	27-72	910	737	76(9)	11(1)	70(8)	668	218(25)
Multiethnic Cohort Study	USA	1993-2004	84,297	45-78	5583	4597	512(10)	367(7)	283(5)	3668	1575(30)
The Netherlands Cohort Study	Netherlands	1986-2007	58,279	54-70	2416	1263	749(33)	557(24)	460(20)	1746	500(22)
The NIH-AARP Diet and Health Study	USA	1995-2006	250,065	50-71	18889	13946	886(5)	540(3)	554(3)	13744	3964(22)
Prostate Cancer Prevention Trial	USA	1994-2003	15,620	55-86	853	792	13(2)	8(1)	7(1)	684	107(14)
The Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial	USA	1993-2008	30,163	55-75	2997	2574	144(5)	90(3)	81(3)	2584	395(13)

Total			842,149		52683	38445	4924	3110	3199	37530	9746
--------------	--	--	---------	--	-------	-------	------	------	------	-------	------

"Localized": defined as cancers with information on stage but are not defined as "periprostatic", i.e. cancers confined within the prostate; "Advanced": defined as cancers with extension to or fixation to adjacent structures other than seminal vesicles, i.e. T4, N1, M1 or fatal; "Advanced (restricted)": same as "advanced" but excluding localized cases and cases with missing stage, who died of prostate cancer during follow-up; "Low grade": Gleason score <8 or well/moderately differentiated; "High grade": Gleason score >=8 or poorly differentiated/undifferentiated

¹Percentages calculated using total number of cases with non-missing data on stage, therefore numbers do not add to 100%; advanced: includes all fatal cancers as an outcome, advanced (restricted) : same as advanced but excludes cases diagnosed with incident localized cancer or incident cancer but with missing stage data, who died of prostate cancer during follow-up (n=1,814)

²Percentages calculated using total number of cases with non-missing data on grade, therefore numbers do not add up to 100%

Table 2. Median intake of dietary factors by studies (10th-90th percentile)¹

Study	Unprocessed red meat (g/d)	Processed meat (g/d)	Poultry (g/d)	Seafood (g/d)²	Eggs (g/d)
Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study	65.1 (35.9 - 113)	60.2 (22.2 - 142)	7.95 (0.00 - 30.4)	32.5 (11.4 - 74.5)	44.6 (18.1 - 96.9)
Beta-Carotene and Retinol Efficacy Trial	44.9 (15.8 - 106)	16.1 (2.79 - 51.4)	13.5 (3.40 - 39.2)	17.6 (2.31 - 46.4)	13.3 (0.00 - 46.7)
CLUE II Campaign Against Cancer and Heart Disease	37.1 (8.6 - 93.6)	17.9 (1.65 - 57.2)	15.4 (3.47 - 41.8)	11.1 (0.00 - 30.7)	12.5 (0.00 - 46.7)
Cancer Prevention Study-II Nutrition Cohort	44.2 (12.8 - 103)	13.1 (0.00 - 45.6)	20.57 (6.00 - 50.0)	17.1 (3.34 - 45.3)	8.36 (0.00 - 28.6)
Cohort of Swedish Men	55.7 (23.3 - 88.9)	32.8 (10.2 - 66.1)	8.87 (7.60 - 25.0)	30.4 (12.7 - 61.6)	15.3 (4.80 - 36.2)
European Investigation into Cancer and Nutrition	49.6 (8.55 - 114)	31.8 (2.40 - 88.3)	15.7 (0.37 - 49.5)	27.8 (4.10 - 78.2)	15.3 (3.50 - 42.5)
Health Professionals' Follow-Up Study	56.4 (18.1 - 134)	6.80 (0.00 - 22.6)	39.2 (19.6 - 79.8)	32.6 (9.00 - 84.4)	7.00 (0.00 - 40.0)
The Japan Public Health Center-Based Study Cohort 1	21.0 (10.3 - 35.3)	4.71 (0.00 - 11.0)	10.7 (0.00 - 25.0)	41.4 (21.4 - 104)	25.0 (10.7 - 50.0)
The Japan Public Health Center-Based Study Cohort 2	10.3 (3.4 - 24.0)	1.40 (0.00 - 4.28)	9.42 (3.10 - 22.0)	53.0 (14.4 - 115)	25.0 (3.50 - 50.0)
Melbourne Collaborative Cohort Study	109 (39.2 - 235)	21.4 (2.80 - 58.7)	24.0 (8.40 - 66.0)	23.5 (8.40 - 61.0)	17.5 (0.00 - 49.4)
Multiethnic Cohort Study	55.0 (12.0 - 146)	14.6 (2.90 - 46.3)	36.3 (11.3 - 101)	18.4 (3.58 - 54.4)	11.5 (2.88 - 39.1)
The Netherlands Cohort Study	63.8 (31.6 - 107)	15.3 (2.90 - 42.0)	10.6 (0.00 - 18.2)	11.5 (0.00 - 33.9)	14.2 (7.10 - 28.5)
The NIH-AARP Diet and Health Study	38.7 (9.0 - 102)	16.7 (3.7 - 53.1)	24.4 (5.81 - 77.6)	14.7 (3.74 - 48.7)	10.7 (0.00 - 25.0)
Prostate Cancer Prevention Trial	40.7 (7.92 - 116)	8.29 (0.53 - 33.5)	29.8 (6.87 - 93.1)	24.2 (3.57 - 72.3)	7.36 (0.00 - 47.3)
The Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial	56.0 (16.7 - 143)	15.5 (3.25 - 51.1)	18.1 (4.10 - 60.7)	21.7 (5.60 - 66.4)	12.1 (1.40 - 42.5)

¹Definition of meat and fish variables: unprocessed red meat included all unprocessed red meats such as beef, pork, lamb and veal but excluding organs; processed meat included all processed meats such as sausages, hot dogs, bacon, ham and luncheon meats; unprocessed poultry included unprocessed meats from birds such as chicken and turkey; seafood included fish and shellfish but excluding fish organs or roe.

²In the Japan Public Health Center-Based Study Cohort 1 and 2 fish intake was measured with shellfish on the FFQ, fish intake was only assessed separately for dry fish, small fish and fish paste intake. In the NIH-AARP Diet and Health Study one question combined shellfish and other fish on the FFQ, fish intake was only assessed separately for tuna and fried fish. Four studies (Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study, Campaign Against Cancer and Heart Disease, Cancer Prevention Study-II Nutrition Cohort and the Netherlands Cohort Study) did not assess shellfish intake therefore seafood intake represents fish intake.

Localized	1.00	1.03 (0.99-1.06)	1.03 (0.99-1.06)	1.03 (0.99-1.08)	1.04 (1.00-1.09)	0.11	0.77	0%	
Advanced ⁵	1.00	1.06 (0.95-1.18)	1.17 (1.06-1.30)	1.02 (0.91-1.15)	1.09 (0.95-1.26)	0.55	0.39	7%	0.55 ¹⁰
Advanced (restricted) ⁶	1.00	1.06 (0.93-1.22)	1.16 (1.02-1.32)	1.04 (0.90-1.20)	1.17 (0.99-1.39)	0.10	0.94	0%	0.21 ¹¹
Fatal ⁷	1.00	1.06 (0.93-1.20)	1.15 (1.02-1.30)	1.05 (0.92-1.21)	1.04 (0.88-1.24)	0.63	0.51	0%	>0.99 ¹²
By grade									
Low	1.00	1.04 (1.00-1.08)	1.04 (1.00-1.08)	1.04 (1.00-1.08)	1.06 (1.01-1.10)	0.17	0.87	0%	
High ⁸	1.00	1.03 (0.96-1.10)	1.03 (0.97-1.10)	0.98 (0.91-1.05)	1.01 (0.90-1.14)	0.75	0.20	29%	0.54 ¹³
Poultry	<5	5-<15	15-<25	25-<45	≥45				
Total	1.00	1.01 (0.97-1.05)	1.03 (0.97-1.10) ³	1.01 (0.95-1.07)	1.05 (1.00-1.09) ⁴	0.33	0.55	0%	
By stage									
Localized	1.00	1.03 (0.97-1.09)	1.07 (1.00-1.14) ³	1.04 (0.97-1.11)	1.07 (1.02-1.13) ⁴	0.26	0.75	0%	
Advanced ⁵	1.00	0.91 (0.82-1.00)	0.84 (0.75-0.94)	0.79 (0.69-0.90)	0.83 (0.70-0.99)	0.29	0.16	30%	0.007 ¹⁰
Advanced (restricted) ⁶	1.00	0.98 (0.86-1.11)	0.86 (0.75-1.00)	0.83 (0.70-0.99)	0.97 (0.79-1.19)	0.44	0.28	19%	0.37 ¹¹
Fatal ⁷	1.00	0.83 (0.72-0.96)	0.79 (0.65-0.95)	0.72 (0.62-0.85)	0.69 (0.59-0.82)	0.16	0.47	0%	<0.001 ¹²
By grade									
Low	1.00	1.02 (0.97-1.08)	1.04 (0.97-1.11) ³	1.03 (0.95-1.11)	1.06 (1.01-1.12) ⁴	0.66	0.78	0%	
High ⁸	1.00	0.97 (0.90-1.06)	1.00 (0.92-1.09)	0.96 (0.88-1.06)	1.00 (0.91-1.10)	0.33	0.71	0%	0.28 ¹³
Seafood	<5	5-<10	10-<20	20-<40	≥40				
Total	1.00	1.05 (1.00-1.11) ³	1.05 (1.01-1.08)	1.05 (1.02-1.09)	1.04 (0.98-1.09)	0.67	0.22	25%	
By stage									
Localized ¹⁴	1.00	1.04 (1.00-1.08) ³	1.06 (1.01-1.11)	1.07 (1.03-1.11)	1.04 (0.97-1.12)	0.38	0.06	46%	
Advanced ⁵	1.00	1.07 (0.95-1.21)	0.98 (0.88-1.08)	0.97 (0.87-1.09)	0.94 (0.82-1.07)	0.73	0.73	0%	0.16 ¹⁰
Advanced (restricted) ⁶	1.00	1.09 (0.93-1.27)	1.02 (0.90-1.17)	1.01 (0.83-1.22)	1.04 (0.88-1.22)	0.59	0.73	0%	0.98 ¹¹
Fatal ⁷	1.00	1.05 (0.90-1.22)	0.90 (0.77-1.04)	0.93 (0.80-1.10)	0.87 (0.72-1.06)	0.40	0.24	24%	0.10 ¹²
By grade									
Low ¹⁴	1.00	1.07 (1.01-1.13) ³	1.07 (1.02-1.12)	1.06 (1.02-1.10)	1.02 (0.94-1.09)	0.38	0.04	49%	
High ⁸	1.00	1.01 (0.94-1.09)	1.00 (0.93-1.07)	1.04 (0.95-1.14)	1.03 (0.95-1.12)	0.17	0.77	0%	0.80 ¹³
Eggs	<5	5-<25	≥25						
Total	1.00	1.01 (0.99-1.03)	0.99 (0.96-1.02)			0.65	0.97	0%	
By stage									

Localized	1.00	1.01 (0.98-1.03)	0.97 (0.94-1.00)	0.09	0.90	0%	
Advanced ⁵	1.00	1.05 (0.98-1.14)	1.14 (1.01-1.28)	0.01	0.24	23%	0.009 ¹⁰
Advanced (restricted) ⁶	1.00	1.06 (0.95-1.18)	1.07 (0.89-1.29)	0.35	0.06	50%	0.02 ¹¹
Fatal ⁷	1.00	1.02 (0.93-1.13)	1.14 (1.00-1.30)	0.01	0.33	13%	0.02 ¹²
By grade							
Low	1.00	0.99 (0.97-1.02)	0.97 (0.94-1.00)	0.06	0.80	0%	
High ⁸	1.00	1.08 (1.00-1.17)	1.06 (0.98-1.15)	0.07	0.31	18%	0.03 ¹³

"Localized": defined as cancers with information on stage but are not defined as "periprostic", i.e. cancers confined within the prostate; "Advanced": defined as cancers with extension to or fixation to adjacent structures other than seminal vesicles, i.e. T4, N1, M1 or fatal; "Advanced (restricted)": same as "advanced" but excluding localized cases and cases with missing stage, who died of prostate cancer during follow-up; "Low grade": Gleason score <8 or well/moderately differentiated; "High grade": Gleason score ≥8 or poorly differentiated/undifferentiated

¹All models multivariate were adjusted for marital status (married (reference (ref)), never married, widowed, divorced), race (Caucasian (ref), African-American, Asian, Hispanic, other), education (<high school (ref), high school, >high school), body mass index (BMI, kg/m²) (<23 (ref), 23-<25, 25-<30, ≥30), height (meter) (<1.70 (ref), 1.70-<1.75, 1.75-<1.80, 1.80-<1.85, ≥1.85), alcohol (g/day) (0 (ref), >0-<5, 5-<15, 15-<30, ≥30), total energy intake (kcal/d, as continuous variable), smoking status (never (ref), past smoker <15 pack years, past smoker ≥15 pack years, current smoker <40 pack years, current smoker ≥40 pack years), prostate cancer family history (no (ref), yes), physical activity (low (ref), medium, high), history of diabetes (no (ref), yes), multivitamin use (no (ref), yes). Age in years and year of questionnaire return were included as stratification variables.

² Grams vs. ounces: 5 g/day = 0.18 ounces/day ; 10g/day=0.35 ounces/day; 25 g/day = 0.88 ounces/day; 40 g/day=1.41 ounces/day; 100 g/day=3.52 ounces/day; 120g/day= 4.23 ounces/day; 1 egg about 50g (1.76 ounces); 25g/day about half an egg per day

³The Japan Public Health Center Study 1 was excluded from this category because this study did not have any cases in this category. The participants in this study who were in this category and were not cases were included in the next highest category.

⁴The Japan Public Health Center Study 2 was excluded from this category because this study did not have any cases in this category. The participants in this study who were in this category and were not cases were included in the next highest category.

⁵The Japan Public Health Center Study 1, the Japan Public Health Center Study 2 and the Prostate Cancer Prevention Trial were excluded from these analyses because these studies had less than 50 advanced prostate cancer cases.

⁶The Beta-Carotene Retinol Efficacy Trial, Campaign Against Cancer and Heart Disease, Japan Public Health Center Study 1, the Japan Public Health Center Study 2, Melbourne Collaborative Cohort Study, and the Prostate Cancer Prevention Trial were excluded from these analyses because these studies had less than 50 advanced (restricted) prostate cancer cases. For egg intake: the Alpha-Tocopherol Beta-Carotene Prevention Study was excluded from this analysis because this study did not have any cases in the reference group.

⁷The Beta-Carotene Retinol Efficacy Trial, Campaign Against Cancer and Heart Disease, Japan Public Health Center Study 1, the Japan Public Health Center Study 2 and the Prostate Cancer Prevention Trial were excluded from these analyses because these studies had less than 50 fatal prostate cancer cases.

⁸The Japan Public Health Center Study 1 and 2 were excluded from the analyses of high grade cancers because these studies had <50 high grade cancer cases.

⁹The Japan Public Health Center Study 1 and 2 were excluded from the analyses of processed meat consumption due to low consumption.

¹⁰Test for common effects : localized vs. advanced cancers

¹¹Test for common effects : localized vs. advanced (restricted) cancers

¹²Test for common effects : localized vs. fatal cancers

¹³Test for common effects : low grade vs. high grade cancers

¹⁴The Japan Public Health Center Study 2 was excluded from the analyses of localized cancers because this study had no cases in the reference group.

Table 4: Multivariate Pooled Relative Risks (RR)¹ and 95% Confidence Intervals (95% CI) for Meat and Egg Consumption and Prostate Cancer Risk by Geographic Region

	Categories (g/d) ²					P-value for test of trend	P-value for test of between-studies heterogeneity, highest category	P-value for test of interaction, highest category
Unprocessed red meat	<20	20-<40	40-<60	60-<100	≥100			
Advanced ³								
North America	1.00	1.07 (0.96-1.20)	1.07 (0.94-1.22)	1.08 (0.96-1.23)	1.19 (1.02-1.39)	0.01	0.37	0.70
Other Continents	1.00	0.86 (0.64-1.16)	0.85 (0.60-1.22)	0.76 (0.52-1.11)	0.82 (0.54-1.26)	0.25	0.02	
Advanced (restricted) ⁴								
North America	1.00	1.05 (0.90-1.22)	1.15 (0.98-1.36)	1.10 (0.93-1.30)	1.30 (1.07-1.57)	0.01	0.78	0.49
Other Continents	1.00	0.93 (0.73-1.19)	1.01 (0.78-1.29)	0.95 (0.74-1.22)	0.96 (0.70-1.33)	0.82	0.35	
Fatal ⁵								
North America	1.00	1.01 (0.87-1.16)	1.00 (0.85-1.17)	1.03 (0.88-1.21)	1.12 (0.85-1.46)	0.18	0.11	0.20
Other Continents	1.00	0.82 (0.59-1.14)	0.84 (0.62-1.13)	0.78 (0.53-1.14)	0.84 (0.54-1.29)	0.37	0.09	
Processed meat	<5	5-<10	10-<20	20-<40	≥40			
Advanced ³								
North America	1.00	1.05 (0.92-1.20)	1.19 (1.06-1.33)	0.95 (0.84-1.08)	1.07 (0.86-1.34)	0.93	0.17	0.08
Other Continents	1.00	1.12 (0.88-1.42)	1.13 (0.92-1.40)	1.24 (1.00-1.53)	1.12 (0.87-1.45)	0.55	0.62	
Advanced (restricted) ⁴								
North America	1.00	1.02 (0.87-1.19)	1.16 (0.98-1.37)	0.95 (0.81-1.13)	1.16 (0.95-1.42)	0.18	0.76	0.36
Other Continents	1.00	1.24 (0.93-1.65)	1.18 (0.91-1.54)	1.29 (0.99-1.69)	1.20 (0.87-1.65)	0.40	0.78	
Fatal ⁵								
North America	1.00	1.05 (0.91-1.22)	1.16 (1.00-1.36)	0.97 (0.83-1.14)	1.02 (0.76-1.36)	0.99	0.19	0.61
Other Continents	1.00	1.07 (0.81-1.42)	1.13 (0.88-1.46)	1.29 (1.00-1.67)	1.11 (0.82-1.51)	0.56	0.78	
Poultry	<5	5-<15	15-<25	25-<45	≥45			
Advanced ³								
North America	1.00	0.86 (0.74-1.01)	0.78 (0.67-0.92)	0.75 (0.64-0.88)	0.77 (0.59-1.00)	0.42	0.10	0.79
Other Continents	1.00	0.94 (0.82-1.07)	0.89 (0.76-1.04)	0.86 (0.69-1.06)	0.92 (0.73-1.17)	0.56	0.52	
Advanced (restricted) ⁴								
North America	1.00	1.01 (0.81-1.25)	0.87 (0.70-1.09)	0.83 (0.66-1.04)	0.89 (0.69-1.15)	0.51	0.33	0.55
Other Continents	1.00	0.96 (0.83-1.12)	0.86 (0.71-1.03)	0.84 (0.63-1.10)	1.12 (0.79-1.58)	0.71	0.25	

Fatal ⁵								
North America	1.00	0.71 (0.58-0.86)	0.65 (0.53-0.79)	0.65 (0.53-0.80)	0.63 (0.51-0.78)	0.23	0.38	0.10
Other Continents	1.00	0.94 (0.81-1.10)	0.97 (0.81-1.16)	0.87 (0.67-1.13)	0.85 (0.63-1.14)	0.54	0.78	
Seafood	<5	5-<10	10-<20	20-<40	≥40			
Advanced ³								
North America	1.00	1.06 (0.92-1.22)	1.00 (0.88-1.15)	0.91 (0.79-1.04)	0.89 (0.76-1.04)	0.11	0.48	0.72
Other Continents	1.00	1.10 (0.86-1.40)	0.93 (0.78-1.11)	1.13 (0.93-1.37)	1.04 (0.82-1.31)	0.12	0.88	
Advanced (restricted) ⁴								
North America	1.00	1.08 (0.90-1.30)	1.01 (0.85-1.20)	0.91 (0.72-1.17)	0.97 (0.79-1.19)	0.52	0.59	0.34
Other Continents	1.00	1.10 (0.82-1.49)	1.04 (0.85-1.28)	1.21 (0.96-1.52)	1.18 (0.89-1.55)	0.04	0.73	
Fatal ⁵								
North America	1.00	1.03 (0.85-1.24)	0.94 (0.76-1.17)	0.84 (0.71-1.00)	0.81 (0.61-1.08)	0.05	0.13	0.11
Other Continents	1.00	1.15 (0.85-1.56)	0.86 (0.69-1.07)	1.10 (0.85-1.42)	1.02 (0.77-1.35)	0.26	0.73	
Eggs	<5	5-<25	≥25					
Advanced ³								
North America	1.00	1.13 (1.03-1.24)	1.27 (1.14-1.42)			<0.001	0.60	0.003
Other Continents	1.00	0.88 (0.76-1.02)	0.92 (0.77-1.11)			0.88	0.96	
Advanced (restricted) ⁴								
North America	1.00	1.15 (1.02-1.30)	1.23 (1.02-1.48)			0.03	0.23	<0.001
Other Continents	1.00	0.84 (0.66-1.08)	0.84 (0.67-1.05)			0.23	0.99	
Fatal ⁵								
North America	1.00	1.10 (0.98-1.23)	1.26 (1.10-1.45)			0.006	0.50	0.02
Other Continents	1.00	0.83 (0.65-1.06)	0.88 (0.73-1.07)			0.80	0.91	

"Localized": defined as cancers with information on stage but are not defined as "periprostic", i.e. cancers confined within the prostate; "Advanced": defined as cancers with extension to or fixation to adjacent structures other than seminal vesicles, i.e. T4, N1, M1 or fatal; "Advanced (restricted)": same as "advanced" but excluding localized cases and cases with missing stage, who died of prostate cancer during follow-up; "Low grade": Gleason score <8 or well/moderately differentiated; "High grade": Gleason score ≥8 or poorly differentiated/undifferentiated

¹All models multivariate were adjusted for marital status (married (reference (ref)), never married, widowed, divorced), race (Caucasian (ref), African-American, Asian, Hispanic, other), education (<high school (ref), high school, >high school), body mass index (BMI, kg/m²) (<23 (ref), 23-<25, 25-<30, ≥30), height (meter) (<1.70 (ref), 1.70-<1.75, 1.75-<1.80, 1.80-<1.85, ≥1.85), alcohol (g/day) (0 (ref), >0-<5, 5-<15, 15-<30, ≥30), total energy intake (kcal/d, as continuous variable), smoking status (never (ref), past smoker <15 pack years, past smoker ≥15 pack years, current smoker <40 pack years, current smoker ≥40 pack years), prostate cancer family history (no (ref), yes), physical activity (low (ref), medium, high), history of diabetes (no (ref), yes), multivitamin use (no (ref), yes). Age in years and year of questionnaire return were included as stratification variables

² Grams vs. ounces: 5 g/day = 0.18 ounces/day ; 10g/day=0.35 ounces/day; 25 g/day = 0.88 ounces/day; 40 g/day=1.41 ounces/day; 100 g/day=3.52 ounces/day; 120g/day= 4.23 ounces/day; 1 egg about 50g (1.76 ounces); 25g/day about half an egg per day

³The Japan Public Health Center Study 1, the Japan Public Health Center Study 2, and the Prostate Cancer Prevention Trial were excluded from these analyses

because these studies had less than 50 advanced prostate cancer cases.

⁴The Beta-Carotene Retinol Efficacy Trial, Campaign Against Cancer and Heart Disease, the Japan Public Health Center Study 1, the Japan Public Health Center Study 2, the Prostate Cancer Prevention Trial and the Melbourne Collaborative Cohort Study were excluded from these analyses because these studies had less than 50 advanced (restricted) prostate cancer cases. For egg intake: the Alpha-Tocopherol Beta-Carotene Prevention Study was also excluded from this analysis because this study did not have any cases in the reference group for egg intake.

⁵The Beta-Carotene Retinol Efficacy Trial, Campaign Against Cancer and Heart Disease, the Japan Public Health Center Study 1, the Japan Public Health Center Study 2, and the Prostate Cancer Prevention Trial were excluded from these analyses because these studies had less than 50 fatal prostate cancer cases.